• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    S

    Spectrum Health

    EST. 1997
    863论文总数
    1.5万引用总数

    Spectrum Health System, commonly known as Spectrum Health, is a not-for-profit, integrated, managed care health care organization based in West Michigan.Spectrum Health's subsidiaries include hospitals, treatment facilities, urgent care facilities, as well as physician practices that serve the western Michigan area. Priority Health is a subsidiary health plan with one million members. Spectrum Health is the largest employer in West Michigan with 31,000 staff, 4,200 physicians and advanced practice providers, including 1,600 members of the Spectrum Health Medical Group, and 3,200 volunteers.In 2012, Spectrum Health System was recognized as one of the Top 50 Integrated Health Care Networks in the United States by IMS Health.

    论文量&引用量时间轴

    机构学者

    论文(863)

    年份
    起
    –
    止
    排序
    1Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
    Jürgen K Rockstroh,Moti N Ramgopal, Adrian Curran Fàbregas,Malcolm Hedgcock,Kimberly A Workowski,Sylvie Ronot-Bregigeon,Isabel Cassetti,Cynthia Brinson,Samir K Gupta,Chien-Ching Hung, Mark O'Reilly,Jihad Slim,

    BACKGROUND:Once-daily, single-tablet regimens have transformed care for persons living with human immunodeficiency virus type 1 (HIV-1); however, challenges to adherence continue to limit effective treatment. Long-acting oral-drug combinations could offer new options with less frequent dose administration. METHODS:We conducted a phase 3, double-blind, randomized, active-controlled, noninferiority trial in 12 countries to evaluate the efficacy and safety of a switch to once-weekly oral islatravir-lenacapavir (ISL/LEN) from once-daily oral bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) in adults in whom HIV-1 had been virologically suppressed for at least 6 months while they were receiving B/F/TAF. Participants were assigned in a 1:1 ratio to receive once-weekly ISL/LEN (2 mg/300 mg) or to continue once-daily B/F/TAF for 96 weeks; all received matched placebo for the alternative regimen. The primary end point was the percentage of participants with an HIV-1 RNA level of 50 copies per milliliter or higher at week 48, as determined by the Food and Drug Administration-defined snapshot algorithm. Noninferiority was determined at a margin of 4 percentage points. RESULTS:A total of 607 participants underwent randomization; 304 were assigned to the ISL/LEN group and 303 to the B/F/TAF group. A total of 21% of the participants were women, 31% were Black, 26% were Hispanic or Latine, and 15% were 65 years of age or older. At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was reported in no participants in the ISL/LEN group and 1 (0.3%) in the B/F/TAF group (difference, -0.3 percentage points; 95.002% confidence interval [CI], -1.4 to 0.8); an HIV-1 RNA level of less than 50 copies per milliliter was reported in 284 (93.4%) and 280 (92.4%), respectively (difference, 1.0 percentage point, 95% CI, -3.2 to 5.2). The mean change in the CD4+ T-cell count at week 48 was -10 cells per microliter with ISL/LEN and -18 cells per microliter with B/F/TAF (least-squares mean difference, 12 cells per microliter; 95% CI, -16 to 39). The trial regimen was discontinued owing to adverse events in 6 participants (2.0%) in the ISL/LEN group and 5 (1.7%) in the B/F/TAF group; serious adverse events occurred in 16 (5.3%) and 14 (4.6%), respectively. CONCLUSIONS:Among persons with virologically suppressed HIV-1, once-weekly oral ISL/LEN was noninferior to once-daily B/F/TAF in maintaining HIV viral load suppression. (Funded by Gilead Sciences and Merck Sharp and Dohme; ISLEND-1 ClinicalTrials.gov number, NCT06630286.).

    2026The New England journal of medicine(2026)
    引用
    AI阅读
    加入学术空间
    2Kidney Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV Across Baseline Egfr Subgroups: Five-Year Real-World Data from the BICSTaR Study
    Alexander Wong,Christoph Stephan, Marcel Lee,Malcolm Hedgcock, Daniel Beer,Claudine Duvivier, Oliver Robineau, Arnaud Desclaux,Rachel Rogers,Nathan Unger, Mo Hu,Rebecca Harrison,
    2026Journal of the American Society of Nephrology(2026)
    引用
    AI阅读
    加入学术空间
    3Switch to Single-Tablet Bictegravir-Lenacapavir from a Complex HIV Regimen (ARTISTRY-1): a Randomised, Open-Label, Phase 3 Clinical Trial.
    Chloe Orkin, Peter J Ruane, Malcolm Hedgcock, Cyril Gaultier,Marcelo H Losso,Benoit Trottier, Thomas Lutz, Mark O'Reilly,Mark Bloch,Jihad Slim,Moti Ramgopal,Simiso Sokhela,

    BACKGROUND:Single-tablet regimens (STRs) revolutionised HIV-1 treatment, improving adherence and clinical outcomes; however, many people cannot take these due to resistance, contraindications, or drug-drug interactions, instead relying on complex multi-tablet regimens. Novel STRs are therefore needed. We aimed to evaluate the efficacy and safety of a novel STR, bictegravir-lenacapavir, in people with HIV-1. METHODS:ARTISTRY-1 was a randomised, open-label, active-controlled, non-inferiority phase 3 trial conducted at hospitals and clinics across 15 countries that enrolled people with HIV-1 with virological suppression on complex regimens. Participants were randomly assigned (using interactive technology, 2:1, stratified by geographical region) to switch to once-daily oral bictegravir-lenacapavir 75 mg/50 mg STR or continued complex regimen. The primary outcome was the proportion of participants with an HIV-1 RNA viral load of 50 copies per mL or higher at week 48 (US Food and Drug Administration Snapshot algorithm), assessed in all randomly assigned participants who received any dose of assigned treatment. This trial (active; enrolment complete) was registered with ClinicalTrials.gov (NCT05502341). FINDINGS:Between Jan 29 and Sept 26, 2024, 729 participants were screened; 557 were randomly assigned and treated (bictegravir-lenacapavir n=371; complex regimen n=186). At baseline, median age was 60 years (range 22-84), HIV treatment duration was 28 years (IQR 22-32); participants were taking a median of three antiretroviral pills per day (range 2-11). At week 48, an HIV-1 RNA viral load of 50 copies per mL or higher was observed in three (1%) participants receiving bictegravir-lenacapavir and two (1%) receiving a complex regimen (difference -0·3%; 95·002% CI -2·3 to 1·8), meeting the non-inferiority margin of 4%. No resistance emerged. Adverse event rates were similar between groups. Six (2%) participants discontinued bictegravir-lenacapavir and one (1%) discontinued their complex regimen due to adverse events. There were five deaths in the bictegravir-lenacapavir group, none of which were deemed related to study drug. Participants reported increased treatment satisfaction after switching to bictegravir-lenacapavir. INTERPRETATION:Bictegravir-lenacapavir STR demonstrated non-inferior efficacy to complex regimens, with a similar safety profile and increased treatment satisfaction. Bictegravir-lenacapavir offers new opportunities for HIV-1 treatment optimisation for people taking complex regimens. FUNDING:Gilead Sciences.

    2026Lancet (London, England)(2026)
    引用
    AI阅读
    加入学术空间
    4Influence of Pulmonary Hypertension on Lung Transplant Survival and Graft Laterality in Interstitial Lung Disease
    T. Stacel, C. Lawson, M. Piekarska, I. Pokora, T. Timek, E. Murphy, R. Girgis
    2026JOURNAL OF HEART AND LUNG TRANSPLANTATION(2026)
    引用
    AI阅读
    加入学术空间
    5Temporalis Muscle Thickness As a Prognostic Factor for 30-Day, 90-Day, and Overall Mortality in Newly-Diagnosed Glioblastoma
    Mohamed Abouelleil,Omar Nabulsi, Sabah Hamidi,Ankush Chandra,Lara Massie,Tarek Mansour, Momina Mustaquim,Mohamed Macki,Tobias Walbert,Adam Robin,Brent Griffith, Bilaluddin Jamaluddin,

    BACKGROUND:Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Accurate prognostic biomarkers are needed to guide care and treatment pathways across the spectrum of age. Temporal muscle thickness (TMT) is an accessible parameter that has been recognized as a prognostic marker for GBM. In addition, frailty, as measured by sarcopenia, has been proven to predict overall survival in other oncologic processes. OBJECTIVE:We evaluated whether sarcopenia, as measured by temporalis muscle thickness, has prognostic value for predicting survival in GBM. We aimed to confirm its prognostic accuracy and compare it to other survival markers. METHODS:A prospective GBM database identified 257 patients undergoing initial diagnostic surgery at Henry Ford Hospital in Detroit, Michigan. Sarcopenia was quantified by temporalis muscle thickness and grouped into tertiles. Mortality hazard ratios were calculated using multivariate analysis. RESULTS:After multivariate analysis, sarcopenia at the time of initial surgery was the only factor associated with mortality at 30 days postoperatively (OR 0.10, P = 0.030). Analysis demonstrated that mortality at 30 days had no association with gender, past medical history, tumor focality, tumor volume, tumor eloquence, or extent of resection. Sarcopenia at initial surgery predicted 90-day postoperative mortality; the most sarcopenic patients (first tertile) had greater mortality than those in the second (OR 0.28, P = 0.021) and third tertiles (OR 0.04, P = 0.003). Sarcopenia predicted overall mortality, greater in the first tertile than the second (OR 0.41, P < 0.001) and third tertiles (OR 0.41, P < 0.001). Sarcopenia compared favorably to other predictors of mortality, including initiation of postoperative temozolomide and radiation treatment (OR 0.27, P < 0.001), gross total resection (OR 0.54, P = 0.007), and O6-methylguanine-DNA methyltransferase (MGMT) methylation status (OR 0.44, P < 0.001). Kaplan-Meier survival curves represent differences in survival (log-rank p < 0.001). CONCLUSIONS:Sarcopenia has prognostic value for predicting postoperative 30-day, 90--day, and overall survival from diagnosis in GBM. The frailty/sarcopenia paradigm is independent of patient demographic, oncologic, genetic, surgical, and therapeutic factors. Temporalis muscle thickness assessment provides a simple method to help guide treatment decisions in affected adult populations.

    2026Cureus(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 863 篇论文

    合作机构(100)

    密歇根州立大学合作论文 140
    密歇根大学合作论文 84
    CACI合作论文 38
    温纳贝戈医学中心合作论文 28
    Helen DeVos Children''s Hospital,Spectrum Health合作论文 24
    北卡罗来纳大学系统合作论文 23
    德克萨斯大学奥斯汀分校合作论文 23
    华盛顿大学合作论文 23
    亨利·福特医疗系统合作论文 20
    威廉·比蒙医院合作论文 19

    机构统计